Head-to-head
MEDVi vs Hims & Hers
Compared on both medications across the eight dimensions this database records. They differ on 8 of those eight. MEDVi is cheaper on all-in tirzepatide at 10 mg/week, though on a flat-versus-tiered matchup the cheaper program can change further up the dose ladder.
The short answer
MEDVi is $399 a month all-in for tirzepatide; Hims & Hers is $697. Over twelve months that is $4,788 against $8,364. Value Scores are 57.4 and 27.5 out of 100.
Tirzepatide
Plan pages: MEDVi plans · Hims & Hers plans
At 10 mg/week, MEDVi is $399 a month all-in and Hims & Hers is $697 — $298 apart, or $3,576 across a year. Over twelve months the totals are $4,788 (billed monthly) and $8,364 (billed monthly).
MEDVi charges a flat $399 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay.
Hims & Hers charges a flat $548 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay. The company publishes no price at 5, 7.5, 12.5, 15 mg, so those doses are left blank rather than estimated.
| Dose | MEDVi | Rank | Hims & Hers | Rank | Cheaper |
|---|---|---|---|---|---|
| 2.5 mg | $399 | 27/31 | $548 | 30/31 | MEDVi by $149 |
| 5 mg | $399 | 15/17 | — | — | only MEDVi publishes |
| 7.5 mg | $399 | 14/17 | — | — | only MEDVi publishes |
| 10 mg | $399 | 21/27 | $548 | 25/27 | MEDVi by $149 |
| 12.5 mg | $399 | 14/17 | — | — | only MEDVi publishes |
| 15 mg | $399 | 14/17 | — | — | only MEDVi publishes |
MEDVi is cheaper at every dose where both publish a price, so the lead does not change as you titrate.
Across the 27 programs this database can rank on tirzepatide, MEDVi sits 21 of 27 on all-in monthly cost and Hims & Hers sits 25. There are 3 other programs priced between them. The field median is $339 and the floor is $169, so both sit above the median. MEDVi is $230 above the cheapest tirzepatide program on record. Hims & Hers is $528 above the cheapest tirzepatide program on record.
LillyDirect (Zepbound), the lowest FDA-approved tirzepatide channel here, is $449 a month — MEDVi undercuts it by $50, Hims & Hers by $-248. Compounded products are not FDA approved; insurance can reverse that comparison.
| Plan term | MEDVi | Hims & Hers | Cheaper |
|---|---|---|---|
| Month to month | $399 | $548 | MEDVi by $149 |
| Settled dose | MEDVi | Hims & Hers | Difference |
|---|---|---|---|
| 2.5 mg | $4,788 | $8,364 | $3,576 apart |
| 5 mg | $4,788 | — | one side unpriced |
| 7.5 mg | $4,788 | — | one side unpriced |
| 10 mg | $4,788 | $8,364 | $3,576 apart |
| 12.5 mg | $4,788 | — | one side unpriced |
| 15 mg | $4,788 | — | one side unpriced |
MEDVi publishes no rate for 3-month term, 6-month term, 12-month term; Hims & Hers publishes none for 3-month term, 6-month term, 12-month term. An unpublished term is not necessarily unavailable — it is unpriced in public, which you can only resolve by asking.
A titration year is not twelve months at the maintenance price. Stepping up roughly four weeks per dose before settling at 10 mg/week, the first twelve months work out to $4,788 on MEDVi and $8,364 on Hims & Hers. The ramp is cheaper than the settled rate on whichever program prices by dose, which is why a first-year quote and a steady-state quote are not the same number.
That calculation is partial: Hims & Hers publishes no price at 2 of them, so the maintenance rate stands in for the missing steps rather than a number the company has stated.
Value Scores are 57.4 for MEDVi and 27.5 for Hims & Hers, against a tirzepatide category floor of $169. MEDVi leads by 29.9 points, and the margin comes from structure rather than price alone.
| Program | Price /70 | Evidence /15 | Dose /10 | Membership /5 | Total /100 |
|---|---|---|---|---|---|
| MEDVi | 29.6 | 12.8 | 10 | 5 | 57.4 |
| Hims & Hers | 17.0 | 10.5 | 0 | 0 | 27.5 |
Semaglutide
Plan pages: MEDVi plans · Hims & Hers plans
At 2.4 mg/week, MEDVi is $299 a month all-in and Hims & Hers is $602 — $303 apart, or $3,636 across a year. Over twelve months the totals are $3,588 (billed monthly) and $7,224 (billed monthly).
MEDVi charges a flat $299 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay.
Hims & Hers charges a flat $453 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay. The company publishes no price at 0.5, 1, 1.7 mg, so those doses are left blank rather than estimated.
MEDVi is cheaper at every dose where both publish a price, so the lead does not change as you titrate.
Value Scores are 58.0 for MEDVi and 25.5 for Hims & Hers, against a semaglutide category floor of $129. MEDVi leads by 32.5 points, and the margin comes from structure rather than price alone.
Where the two programs differ
All-in monthly
MEDVi is cheaper month to month — $399 against $697, a gap of $298 every month, or $3,576 across a year if both rates hold.
Cancellation terms
Cancellation differs: MEDVi states Cancel before renewal, while Hims & Hers states Cancel anytime. Read this next to the twelve-month figures — a prepaid discount and a restrictive refund policy are the same decision.
Commitment
MEDVi asks for Month-to-month; Hims & Hers asks for Membership month-to-month ($39 first month). This is the dimension most likely to change which program is actually cheaper for you, because the lowest rates on both sides are usually attached to the longest terms.
Dose policy
MEDVi charges one price at every dose; Hims & Hers prices by dose. That difference usually matters more than the headline gap, because the tiered program's advertised figure describes the dose you start on, not the dose you settle at.
Evidence status
The two prices are not equally well evidenced. MEDVi's figure is provider-stated and Hims & Hers's is reported. MEDVi rests on the stronger of the two, and the Value Score below reflects that — evidence quality is worth fifteen points and is not a tiebreaker we apply after the fact.
Membership fee
Hims & Hers charges a membership of $149 a month on top of the medication. That is already folded into the all-in figures above — it is broken out here because a membership is a recurring charge that continues even in a month you skip a shipment.
Shipping
Hims & Hers bills shipping separately at $5; the other includes it.
Twelve-month cost
Over twelve months the totals are $4,788 for MEDVi and $8,364 for Hims & Hers. MEDVi is lower by $3,576 — a figure worth checking against the cancellation terms below, because a prepaid year is only cheaper if you stay on it.
What each record says
MEDVi Official site
MEDVi advertises a $179 semaglutide start that tiers to $299 at maintenance; tirzepatide is $399 flat.
It does not publicly name its compounding pharmacy; the record shows Partner pharmacies, so who actually makes the medication cannot be independently verified; commitment terms are Month-to-month; cancellation is Cancel before renewal; availability is stated as Most US states.
Evidence: provider-stated — taken from the provider's own published pages; checkout capture pending, captured . Source — medvi.com pricing capture 2026-08-05
Watch: Start-vs-maintenance spread on semaglutide; compare on maintenance.
Hims & Hers Official site
After settling with Novo Nordisk on March 9, 2026 and exiting compounded semaglutide for new patients, Hims & Hers now runs a branded-only GLP-1 service: Wegovy injection $299/month, oral Wegovy $249/month, and Zepbound $399/month, on top of a $149/month membership ($39 first month) plus $5 shipping.
It names its compounding pharmacy — Brand fulfillment (Wegovy, oral Wegovy, Zepbound) + partner pharmacy, recorded as Brand channel — which can be checked against state board licensing and FDA inspection records before you order; commitment terms are Membership month-to-month ($39 first month); cancellation is Cancel anytime; availability is stated as 50 states.
Evidence: reported — sourced from dated third-party reporting; first-party capture pending, captured . Source — Post-settlement pricing reported May–Jun 2026 (Wegovy $299 / oral $249 / Zepbound $399 + $149 membership + $5 shipping); first-party checkout capture pending
Watch: The membership is the number that moves the math: a $299 Wegovy pen becomes ~$453/month all-in. Compare against going to NovoCare or LillyDirect directly.
What neither record tells you
MEDVi does not publish
- no published twelve-month tirzepatide rate
- no published twelve-month semaglutide rate
- no named compounding pharmacy
- no state-by-state availability list — it says Most US states
Hims & Hers does not publish
- no tirzepatide price at 5, 7.5, 12.5, 15 mg per week
- no published twelve-month tirzepatide rate
- no semaglutide price at 0.5, 1, 1.7 mg per week
- no published twelve-month semaglutide rate
Ask MEDVi and Hims & Hers for each of those in writing before enrolling. A gap is not evidence of a problem; it does mean nothing can be checked against it.
What would change this answer
Evidence may be upgraded. Hims & Hers carries a price we have not captured at checkout. A capture would move the evidence term and could reorder these two without any price changing.
Which one suits which reader
On the lowest standing monthly rate for tirzepatide, MEDVi Official site wins this matchup. If you expect to titrate to the top of the ladder, medvi's flat pricing is worth more than the headline gap suggests; if you want to be able to pause without still paying, medvi carries no membership; and if you would rather trust a better-evidenced number, medvi's price rests on stronger provenance.
Both figures should be checked at the provider's own checkout before you pay. MEDVi's tirzepatide price is provider-stated as of 2026-08-05; Hims & Hers's is reported as of 2026-08-11.
Questions
Is MEDVi or Hims & Hers cheaper for tirzepatide?
MEDVi is cheaper on all-in monthly cost at 10 mg/week: $399 against $697, a difference of $298 a month. All-in means the medication plus every mandatory recurring fee.
What is the twelve-month cost of MEDVi versus Hims & Hers?
MEDVi works out to $4,788 across twelve months and Hims & Hers to $8,364, on the plan terms each publishes.
Does MEDVi or Hims & Hers raise the price as the dose goes up?
MEDVi: no, it charges one flat rate at every dose. Hims & Hers: yes, it prices by dose. Where one program is flat and the other is tiered, the cheaper of the two can change as you titrate upward.
How many ways do MEDVi and Hims & Hers differ?
8 of the eight dimensions this site records: all-in monthly, twelve-month cost, dose policy, membership, shipping, commitment, cancellation terms and evidence status.
Which of MEDVi and Hims & Hers names its pharmacy?
Hims & Hers does — Brand fulfillment (Wegovy, oral Wegovy, Zepbound) + partner pharmacy. MEDVi does not, recording only Partner pharmacies, so who makes its medication cannot be independently verified.
How well evidenced are the MEDVi and Hims & Hers prices?
MEDVi's tirzepatide figure is provider-stated — taken from the provider's own published pages; checkout capture pending — captured 2026-08-05. Hims & Hers's is reported, captured 2026-08-11. Evidence status is worth fifteen points in the Value Score, so it is priced in rather than mentioned as an aside.
Which is cheaper for semaglutide?
MEDVi, at $299 a month all-in against $602 at 2.4 mg/week. The two programs do not necessarily lead on both medications.
Official sources: MEDVi official site · Hims & Hers official site. Compounded tirzepatide and semaglutide are not FDA-approved products.